This Week in General Medicine — Jul 31, 2026

Welcome to This Week in General Medicine. This week we're covering 3 notable papers spanning novel therapeutic approaches for glycemic control in type 2 diabetes and updated clinical management strategies for bulimia nervosa. Let's dive in.

We begin with a major development in diabetes care published in The Lancet, which simultaneously released two phase-two trials investigating zenagamtide, a novel unimolecular peptide agonist that targets glucagon-like peptide-1, amylin, and calcitonin receptors [1], [2]. This dual-targeting mechanism represents a new frontier in metabolic medicine, combining the insulin-stimulating and appetite-suppressing effects of glucagon-like peptide-1 with the satiety-promoting actions of amylin. In the first trial, investigators evaluated once-weekly subcutaneous injections of zenagamtide across six maintenance doses ranging from point-four milligrams to forty milligrams in adults with type 2 diabetes who were already taking metformin with or without a sodium-glucose cotransporter-2 inhibitor [1]. This thirty-six-week, randomized, parallel, double-blind, placebo-controlled, dose-finding study was conducted across eighty-three hospital and clinic sites in eleven countries, enrolling patients aged eighteen to seventy-five with a baseline glycated hemoglobin between seven and ten percent and a body-mass index ranging from twenty-three to just under fifty. Over the thirty-six-week treatment period, which featured a starting dose of point-two milligrams and gradual dose escalations every four weeks, subcutaneous zenagamtide led to substantial, dose-dependent reductions in glycated hemoglobin from an overall baseline mean of seven-point-eight percent. For patients on the lowest maintenance dose of point-four milligrams, glycated hemoglobin dropped by point-nine percent, which was point-seventy-seven percentage points lower than the placebo group. At the highest maintenance dose of forty milligrams, the reduction was even more pronounced, with a drop of one-point-seven percent, representing an estimated treatment difference of more than one-and-a-half percentage points compared to placebo. The safety profile was consistent with other glucagon-like peptide-1 and amylin-based therapies, with gastrointestinal symptoms being the most common adverse events, which were mostly mild to moderate in severity. Serious adverse events were reported in twenty-one of the two hundred and sixty-one treated participants, and no deaths occurred during the study.

Recognizing that many patients prefer oral options over injections, the second Lancet trial evaluated once-daily oral zenagamtide at maintenance doses of six, twenty-five, and fifty milligrams in a highly similar patient population [2]. This trial utilized the same inclusion criteria, enrolling adults with type 2 diabetes and a body-mass index of twenty-three to under fifty who were on stable metformin with or without a sodium-glucose cotransporter-2 inhibitor. The treatment began with a starting dose of one-point-five milligrams and escalated every four weeks to the target maintenance doses. Over thirty-six weeks, oral zenagamtide demonstrated significant, dose-dependent improvements in glycemic control from baseline glycated hemoglobin levels that averaged between seven-point-nine and eight-point-one percent. Patients taking the six-milligram dose achieved a point-nine percent reduction in glycated hemoglobin, which was point-five percentage points lower than placebo. Those on the twenty-five-milligram dose achieved a one-point-three percent reduction, and patients on the fifty-milligram dose saw a decrease of one-point-four percent, translating to an estimated treatment difference of slightly over one percentage point compared to placebo. As expected, gastrointestinal adverse events were the most frequent side effects, occurring in twenty-six percent of participants in the six-milligram group, forty-one percent in the twenty-five-milligram group, and forty-seven percent in the fifty-milligram group, compared to twenty-three percent in the placebo group. Serious adverse events were reported in seven of the one hundred and eighty-six participants receiving active treatment, and no serious adverse events were seen in the placebo group. There were no deaths, and the overall safety and tolerability profile of the oral formulation was consistent with other glucagon-like peptide-1 and amylin receptor agonists.

Transitioning from metabolic health to psychiatric care, a comprehensive review published in Nature Reviews Disease Primers provides a vital update on bulimia nervosa, a common eating disorder that carries a substantial global burden [3]. The authors highlight that bulimia nervosa is characterized by recurrent episodes of binge eating followed by extreme compensatory behaviors, such as self-induced vomiting, misuse of laxatives, fasting, or excessive exercise, driven by an intense preoccupation with body weight, shape, and image. The primer notes that while cognitive behavioral therapy remains the established, first-line psychological treatment, there remains a massive treatment gap, with many individuals going undiagnosed or failing to access evidence-based care. To address this, the field is moving toward increasing the accessibility of treatments through digital adaptations, low-cost delivery models, and the active integration of lived-experience expertise in clinical research. Furthermore, emerging insights into the neurobiology of eating disorders are beginning to pave the way for more targeted psychological and biological interventions, highlighting the need for general medicine clinicians to screen early and facilitate prompt referral to specialized therapies.

If you only have time for one paper this week, make it the phase-two trial of once-daily oral zenagamtide [2]. This study is particularly practice-changing for general medicine physicians because it demonstrates that a highly effective, next-generation dual-agonist can be delivered orally, offering a powerful, non-invasive alternative for type 2 diabetes management that aligns with patient preference and could significantly improve long-term adherence.

Here are the key takeaways from this week in General Medicine. First, the novel unimolecular agonist zenagamtide, which targets glucagon-like peptide-1, amylin, and calcitonin receptors, shows robust glycemic efficacy in type 2 diabetes when administered either as a once-weekly subcutaneous injection or a once-daily oral tablet [1], [2]. Second, subcutaneous zenagamtide at its highest dose of forty milligrams achieved a substantial reduction in glycated hemoglobin of one-point-seven percent over thirty-six weeks [1]. Third, once-daily oral zenagamtide achieved up to a one-point-four percent reduction in glycated hemoglobin, offering a highly effective non-injectable option with a similar safety profile [2]. Fourth, gastrointestinal side effects remain the most common adverse events for both formulations, consistent with existing class effects [1], [2]. Finally, for bulimia nervosa, cognitive behavioral therapy remains the first-line treatment, but clinicians must focus on early detection and utilizing digital or accessible treatment adaptations to help bridge the significant global treatment gap [3].

That's your roundup for This Week in General Medicine. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week. One more note before you go: only 3 new papers of note met the bar since the last update — a quieter stretch for new literature. Still worth revisiting from recent updates: What to Know About the First CKM Syndrome Guidelines, in JAMA; and Global Cardiology Groups Issue New Universal Definition of Heart Failure, in JAMA.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.